Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

M. Lokhorst, Henk; Plesner, Torben; P. Laubach, Jacob; Nahi, Hareth; Gimsing, Peter; Hansson, Markus; C. Minnema, Monique; Lassen, Ulrik; Krejcik, Jakub; Palumbo, Antonio; W.C.J. van de Donk, Niels; Ahmadi, Tahamtan; Khan, Imran; Uhlar, Clarissa; Wang, Jianping; Kate Sasser, A.; Losic, Nedjad; Lisby, Steen; Basse, Linda; C. Brun, Nikolai; G. Richardson, Paul

doi:10.1056/nejmoa1506348

Public

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Published in New England Journal of Medicine • Aug 26, 2015

Authors:

Henk M. Lokhorst

Torben Plesner

Jacob P. Laubach

Abstract

BACKGROUND: Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS: In part 1, t...

Subject

Daratumumab

CD38

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!